Psyence Biomedical (PBM) stock continued to rally on Friday following the release of a filing with the U.S. Securities and Exchange Commission (SEC). This SEC filing was focused on an expansion in Australia for its clinical site network. The company has expanded the number of these locations to five from three, allowing it to better conduct clinical trials.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Psyence Biomedical noted that its ongoing Phase IIb clinical trial of natural psilocybin for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting will directly benefit from this expansion. The company expects it to strengthen recruitment and accelerate enrollment. Psyence Biomedical has provided its pharmaceutical-grade psilocybin product, NPX-5, for this trial.
Jody Aufrichtig, CEO of Psyence BioMed, said, “This expansion marks an important step forward in scaling the clinical infrastructure required to advance NPX-5 and support ongoing patient dosing. By adding high-quality clinical partners such as Ramsay Health Care and NeuroCentrix, we are strengthening our ability to execute efficiently, accelerate enrollment, and generate meaningful clinical data. As patients continue to be dosed with NPX-5, our focus remains on advancing the program through a disciplined, regulatory-aligned pathway.”
Psyence Biomedical Stock Movement Today
Psyence Biomedical stock was up 69.85% in pre-market trading on Friday, following a 103.82% rally yesterday. The stock has also increased 24.68% year-to-date but was still down 73.1% over the past 12 months.
PBM stock experienced heavy trading activity alongside today’s rally. This saw some 23.9 million shares change hands this morning, compared to a three-month average daily trading volume of about 1.12 million shares.
Is Psyence Biomedical Stock a Buy, Sell, or Hold?
Turning to Wall Street, traditional analyst coverage of Psyence Biomedical is lacking. Instead, let’s see what the TipRanks technical sentiment tool can show traders about the stock. The Overall Consensus for PBM is Neutral, based on 10 Bearish, three Neutral, and nine Bullish indicators.
